:quality(75)/cloudfront-us-east-1.images.arcpublishing.com/elcomercio/GERBNCQRLZHXJPBYJYPJ7BY7HQ.JPG)
Akero Therapeutics, a clinical-stage company based in South San Francisco, California, is dedicated to developing innovative treatments for patients with serious metabolic diseases that have high unmet medical needs. The company recently announced that its management will be presenting at the BofA Securities 2024 Health Care Conference on May 14, 2024, at 5:00 p.m. Pacific Time in Las Vegas, Nevada. Those interested can tune into a live webcast of the presentation on the investor relations section of Akero Therapeutics’ website, www.akerotx.com. An archived replay will also be available on the website for those who miss the live broadcast.
Akero Therapeutics is currently focusing on developing treatments for metabolic diseases such as MASH and is excited to share its progress with investors and stakeholders at the upcoming conference. The company’s lead product candidate, EFX, is undergoing evaluation in several clinical trials including the SYMMETRY study for patients with compensated cirrhosis due to MASH (F4 fibrosis), which has already been completed and positive results were reported from this Phase 2b trial. In addition to this study, Akero Therapeutics has two ongoing Phase 3 clinical trials – SYNCHRONY Histology and SYNCHRONY Real-World studies for patients with pre-cirrhotic MASH (F2-F3 fibrosis) and MASH (F1-F3 fibrosis) or MASLD respectively. Another Phase 3 clinical trial – SYNCHRONY Outcomes study – is scheduled to begin in the second quarter of 2024 for patients with compensated cirrhosis due to MASH (F4 fibrosis). These studies build upon the positive results of previous Phase 2b clinical trials and are helping Akero Therapeutics bring innovative treatments to market for patients suffering from these debilitating conditions.
For investors looking to get in touch with Akero Therapeutics, they can reach out to Christina Tartaglia of Stern Investor Relations, Inc., at [insert email/phone number]. For media inquiries, Sarah O’Connell can be contacted at [insert email/phone number]. To learn more about Akero Therapeutics and their work towards treating metabolic diseases such as MASH please visit their website [www.[insert website name]].
